| Biomarker ID | 1613 |
| PMID | 31035590 |
| Year | 2019 |
| Biomarker | SMAD3 [SNP: rs7162912; G vs T] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.04 (95% CI: 1.43–2.92) |
| Effect on Pathways | Pathways include: NF-kappaB activation by non-typeable Hemophilus influenzae, Integrated cancer pathway, Androgen receptor signaling, proteolysis, and transcription regulation, Myc active pathway,Transcriptional activity of SMAD2/SMAD3-SMAD4 heterotrimer |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 418 patients in the training cohort (80 experiencing Biochemical Recurrence) and 131 patients in the validation cohort (28 experiencing Biochemical Recurrence) were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0001 |
| Method Used | Allele specific PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |